Winston Dunn, MD, , FAASLD

Winston Dunn, MD, FAASLDProfessor of Medicine, Division of Gastroenterology, University of Kansas Medical CenterDr. Winston Dunn is a hepatologist and Professor of Medicine at the University of Kansas Medical Center, specializing in metabolic dysfunction–associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and advanced fibrosis. His research integrates clinical epidemiology, real-world data, and machine learning to improve noninvasive diagnostics and patient stratification for therapeutic trials.Dr. Dunn is the principal investigator for multiple Phase 3 trials, including those involving resmetirom, lanifibranor, semaglutide, and pegozafermin, and has led NIH- and industry-supported studies on fibrosis regression and models of care in NASH. He has authored over 80 peer-reviewed publications in journals such as Hepatology, The New England Journal of Medicine, Journal of Hepatology, and The American Journal of Gastroenterology.At the 2025 AASLD Liver Meeting, Dr. Dunn is presenting work on:Sex-specific binge drinking thresholds and fibrosis risk in the U.S. populationPopulation screening strategies for significant fibrosis in MASLD using SAFE and ALADDIN modelsFAST AND CAP SCORES AS EARLY BIOMARKERS OF TREATMENT RESPONSE IN MASLD PATIENTS RECEIVING RESMETIROM: A REAL-WORLD STUDYDr. Dunn is a Fellow of the American Association for the Study of Liver Diseases (FAASLD) and an active member of the AASLD Alcohol-Associated Liver Disease SIG. His work focuses on bridging translational research and clinical application to advance precision hepatology in the era of disease-specific therapy.